CYTOSORBENTS MEDICAL INC

PRINCETON, NJ · UEI LSF2KFUSY4K7 · CAGE 5E0N2

Small businessSmall-business set-aside

SAM.gov registration active · expires December 12, 2026(as of the monthly SAM public extract)

Awarded (5-yr transactions)

Set-aside awards seen

Latest period end

Dec 2026

Largest contract awards

W81XWH22C0046$4.3M
AWARD OF CYTOSORBENTS DHA SBIR PH III MED R&D CONTRACT FOR "INTEGRATING ISOAGGLUTININ REDUCTION FOR A UNIVERSAL DRIED PLASMA PRODUCT FOR BATTLEFIELD AND FIRST RESPONDER USE"
Defense Health Agency · NAICS 541715 · Aug 2022 – Dec 2026 · official record ↗
W81XWH20C0050$2.9M
AWARD OF CYTOSORBENTS' DHA STTR RIF PHASE III MEDICAL R&D CONTRACT FROM PROPOSAL DHP15B-001-P-6144 FOR "DEVELOPMENT OF A HIGHLY EFFICIENT ADSORBER TO REMOVE ANTI-A AND ANTI-B ANTIBODIES FROM BLOOD AND PLASMA FOR TRANSFUSION"
Department of the Army · NAICS 541715 · Jun 2020 – Oct 2023 · official record ↗
FA865019C6065$2.8M
K+ONTROL RENAL SUPPORT SYSTEM FOR REDUCTION OF HYPERKALEMIA - RIF
Department of the Air Force · NAICS 541715 · Sep 2019 – Sep 2023 · official record ↗
HHSN268201600006C$1.5M
IGF::OT::IGF TO DEVELOP HEMODEFEND, HEMOCOMPATIBLE, HIGHLY POROUS POLYMER BEADS OPTIMIZED TO BROADLY REMOVE FREEHEMOGLOBIN, POTASSIUM, REACTIVE ANTIBODIES, AND INFLAMMATORY OR REACTIVE SUBSTANCES FROM BLOOD BASED ON A PROVENPORE CAPTURE AND SURFACE ADSORPTION TECHNOLOGY PLATFORM.
National Institutes of Health · NAICS 541712 · Oct 2015 – Sep 2018 · official record ↗
W81XWH21C0045$1.5M
MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR SEQUENTIAL PH II PROPOSAL NO. H2S-0011 TITLED INVESTIGATION OF A POTASSIUM ADSORBER FOR THE TREATMENT OF HYPERKALEMIA INDUCED BY TRAUMATIC INJURY AND ACUTE KIDNEY INJURY IN AUSTERE MEDICINE.
Defense Health Agency · NAICS 541715 · Apr 2021 – Feb 2025 · official record ↗
W81XWH12C0038$1.2M
SBIR PHASE I - (A112-105-0585)
Department of the Army · NAICS 541712 · Dec 2011 – Oct 2017 · official record ↗
W81XWH20C0087$1.1M
MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR PHASE II PROPOSAL NO. H2S-0005 TITLED DEVELOPMENT OF AN EFFECTIVE ADSORBER TO REMOVE ANTI-A AND ANTI-B ANTIBODIES FROM PLASMA FOR TRANSFUSION.
Department of the Army · NAICS 541715 · Sep 2020 – Jan 2024 · official record ↗
W911QY17C0007$1000K
IGF::OT::IGF PHASE II SBIR
Department of the Army · NAICS 541712 · Feb 2017 – Jan 2019 · official record ↗
W81XWH17C0142$1000K
IGF::OT::IGF DHA SBIR PHASE II PROPOSAL H2-0210
Department of the Army · NAICS 541712 · Sep 2017 – Feb 2020 · official record ↗
FA864923P0420$75K
NOVEL ORAL SORBENT THERAPY FOR THE PREVENTION AND TREATMENT OF TRAVELERS DIARRHEA
Department of the Air Force · NAICS 541715 · Nov 2022 – Feb 2023 · official record ↗
FA864923P0777$75K
NOVEL SORBENT TECHNOLOGY FOR THE RAPID TREATMENT OF ACUTE JOINT INJURY AND INFLAMMATION
Department of the Air Force · NAICS 541715 · May 2023 – Aug 2023 · official record ↗

Is this your company?

Claim it free on GovScout: matched SAM.gov opportunities for your NAICS codes, incumbent intel on every recompete, and monitoring so your SAM registration never lapses.

Claim your profile — free

Public records from FPDS (via USAspending.gov) and SAM.gov. Figures reflect harvested award data and may not be complete; verify against the linked official records. Not an endorsement. Company in the data by mistake or wish to update it? Email support@usegovscout.com.